<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022030</url>
  </required_header>
  <id_info>
    <org_study_id>20210602</org_study_id>
    <nct_id>NCT05022030</nct_id>
  </id_info>
  <brief_title>First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes</brief_title>
  <acronym>CAPCET</acronym>
  <official_title>First-line Treatment of mCapOX Plus Cetuximab Versus mFOLFOX6 Plus Cetuximab for Metastatic Left-sided CRC Patients With Wild-type RAS/BRAF Genes: a Multicenter, Randomised, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety&#xD;
      of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided&#xD;
      CRC patients with wild-type RAS and BRAF genes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients, who meet the inclusion criteria and have signed the informed consent, will be&#xD;
      randomly assigned (1:1 ratio) to receive mCapOX plus cetuximab regimen (arm A) and mFOLFOX6&#xD;
      plus cetuximab regimen (arm B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression free survival is defined as the period from randomization to disease progress or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of complete response and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of complete response, partial response and stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Overall survial is defined as the period from randomization to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>3 years</time_frame>
    <description>The rate of adverse event after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Capecitabine</condition>
  <condition>Cetuximab</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mCapOX (capecitabine+oxaliplatin) plus cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFOX6 (fluorouracil+leucovorin+oxaliplatin) plus cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mCapOX plus cetuximab</intervention_name>
    <description>capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6 plus cetuximab</intervention_name>
    <description>oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent and can understand and comply with the&#xD;
             requirements of the study;&#xD;
&#xD;
          -  Men and women ≥ 18 years of age;&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed metastatic left-sided&#xD;
             colorectal adenocarcinoma with wild-type RAS and BRAF genes;&#xD;
&#xD;
          -  Presence of at least one evaluable lesion, as defined in RECIST Version 1.1;&#xD;
&#xD;
          -  With an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1;&#xD;
&#xD;
          -  No palliative first-line chemotherapy, targeted, immunotherapy, or prior&#xD;
             platinum-based adjuvant chemotherapy, relapse more than 12 months from the end of&#xD;
             adjuvant chemotherapy;&#xD;
&#xD;
          -  According to the imaging findings and surgical assessment of initial unresectable,&#xD;
             synchronous metastatic colorectal cancer, no serious complications of the primary&#xD;
             tumor (obstruction, perforation, massive hemorrhage that cannot be treated in internal&#xD;
             medicine, etc.) ;&#xD;
&#xD;
          -  Life expectancy of longer than 3 months ( clinical assessment);&#xD;
&#xD;
          -  Requirements for lab indicators neutrophils ≥ 1.5 × 109/L, platelets ≥ 75 × 109/L,&#xD;
             hemoglobin ≥ 8 g/dL, total bilirubin ≤ 1.5 × upper limit of normal (UNL); ASAT (SGOT)&#xD;
             and/or ALAT (SGPT) ≤ 2.5 × UNL (≤ 5 × UNL if liver metastases); alkaline phosphatase ≤&#xD;
             2.5 × UNL (≤ 5 × UNL if liver metastases, ≤ 10 × UNL if bone metastases); LDH &lt; 1500&#xD;
             U/L; creatinine clearance (calculated according to Cockcroft and Gault formula) &gt; 50&#xD;
             mL/min or serum creatinine ≤ 1.5 × UNL;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with mCRC who were initially resectable with R0 resection or radiofrequency&#xD;
             or SBRT were excluded.&#xD;
&#xD;
          -  Patients diagnosed with MSI-H or dMMR by PCR or immunohistochemistry&#xD;
&#xD;
          -  Hypersensitivity to any therapeutic agent.&#xD;
&#xD;
          -  Patients who received adjuvant chemotherapy containing oxaliplatin and fluorouracil&#xD;
             within 12 months before entering the study;&#xD;
&#xD;
          -  Patients who have failed one or more palliative chemotherapy regimens;&#xD;
&#xD;
          -  Patients with uncontrolled hepatitis B virus&#xD;
&#xD;
          -  Peripheral neuropathy ≥ CTC grade 2;&#xD;
&#xD;
          -  Neurological or psychiatric disorders affecting cognitive performance;&#xD;
&#xD;
          -  Patients with central nervous system metastasis could not be controlled with&#xD;
             radiotherapy;&#xD;
&#xD;
          -  Previous enteritis, chronic diarrhea, or recurrent bowel obstruction; uncontrolled&#xD;
             bleeding from internal medicine; bowel perforation&#xD;
&#xD;
          -  Uncontrolled concomitant diseases within 6 months before the study, including unstable&#xD;
             angina, acute myocardial infarction, cerebrovascular accident, etc.;&#xD;
&#xD;
          -  Pregnant or lactating patients, or those of childbearing potential who do not take&#xD;
             adequate contraceptive measures;&#xD;
&#xD;
          -  History of other malignancies, but no disease-free survival longer than 5 years;&#xD;
&#xD;
          -  Patients concurrently receiving other anti-tumor treatment or participating in other&#xD;
             interventional clinical trials;&#xD;
&#xD;
          -  Patients who are unable to comply with this study for psychological, family or social&#xD;
             reasons.&#xD;
&#xD;
          -  Patients with other serious diseases that the investigator considers not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng Qiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaofen Li, M.D.</last_name>
    <phone>+86-28-85422589</phone>
    <email>lxf0827@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofen Li, M.D.</last_name>
      <phone>+86-28-85422589</phone>
      <email>lxf0827@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Meng Qiu</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

